Xofigo
·
- Prescription status not stated
- Everything that fits nowhere else, such as contrast media
- Active substance
- Radium Ra223 dichloride
- Made by
- Bayer AG
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Xofigo is indicated for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
SpainNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Bayer AG |
|---|---|
| Active substance | Radium Ra223 dichloride |
| Used in | Everything that fits nowhere else, such as contrast media |
| Classification | V10XX03 · Everything that fits nowhere else, such as contrast media |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Authorised on | 2013-11-13 |
| Last updated by the regulator | 2026-07-30 |
| EMA product number | EMEA/H/C/002653 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).